Skip to main content
Autobound logo
Adicet Bio, Inc.SEC 8-K

Adicet Bio launching pivotal clinical trial in Q4 2026 after positive Phase 1 data for Prula-cel.

Read at SEC EDGAR

What happened

The company is advancing its lupus drug, Prula-cel, to a pivotal study, a major strategic step requiring significant investment in clinical data management, patient analysis, and regulatory reporting infrastructure.

Source

Extracted by Autobound

From the Signal API record
Signal
SEC 8-K

What this signalsFilings often name leadership changes, deals and spending plans.

Filed
Sep 28, 2026

More SEC 8-K signals at other companies

The full record

From the Signal API record

Details

CIK
1720580
Accession number
0001720580-26-000060
Timeframe
Current quarter
Filing year
2026
Fiscal year end
09/28
Why it matters
Target for data vendors
Signal category
Technology

Topics and mentions

Regions named

  • U.S.

Vendors named

  • U.S. Food and Drug Administration (FDA)

Technologies named

  • CAR-T

Extraction

Confidence
High
Relevance
85%
Sentiment
Positive
Detected
Sep 29, 2026
signal_type
sec-8k
signal_subtype
dataInvestment

Use this data

Get every SEC 8-K signal for Adicet Bio, Inc. and the companies you sell to, in the tools you already use.

  1. Ask Claude about it

    Connect Autobound to Claude, Claude Code or Cursor with MCP. Then ask: “What changed at Adicet Bio, Inc. this week?”

    MCP setup guide

  2. Send it to your own tools

    The Signal API returns SEC 8-K signals for any list of companies as JSON, for your CRM, warehouse or app.

    Signal API

  3. Try it free

    Sign up and spend your free credits on the companies you sell to.

    Start Free1,000 free credits

The API returns more than this page shows

This page shows a preview. The full sec-8k record in the Signal API and MCP can also have these 8 fields. Some fields are empty for some signals.

Company

  • linkedin_urlValue in the API
  • industriesValue in the API
  • employee_count_lowValue in the API
  • employee_count_highValue in the API
  • revenueValue in the API
  • descriptionValue in the API

Signal

  • signal_nameValue in the API
  • associationValue in the API
Start Free1,000 free creditsUse it in Claude via MCP
Show the full JSONThe record on this page and the API request

GET /v1/signals/8ae5022e-8fa7-4e82-9cec-4c3cca6aea6e returns this record as JSON. POST /v1/companies/enrich returns every signal for adicetbio.com.

{
  "signal_id": "8ae5022e-8fa7-4e82-9cec-4c3cca6aea6e",
  "signal_type": "sec-8k",
  "signal_subtype": "dataInvestment",
  "detected_at": "2026-09-29T08:08:07.975+00:00",
  "company": {
    "name": "Adicet Bio, Inc.",
    "domain": "adicetbio.com"
  },
  "data": {
    "detail": "The company is advancing its lupus drug, Prula-cel, to a pivotal study, a major strategic step requiring significant investment in clinical data management, patient analysis, and regulatory reporting infrastructure. This creates an immediate need for vendors supporting large-scale clinical trials, particularly those with expertise in data capture, analytics, and FDA compliance.",
    "metrics": {
      "timeframe": "current_quarter"
    },
    "summary": "Adicet Bio launching pivotal clinical trial in Q4 2026 after positive Phase 1 data for Prula-cel.",
    "relevance": 0.85,
    "sentiment": "positive",
    "confidence": "high",
    "source_url": "https://www.sec.gov/Archives/edgar/data/1720580/000172058026000060/acet-20260928.htm",
    "filing_date": "2026-09-28",
    "filing_year": 2026,
    "fiscal_year_end": "09/28",
    "sales_relevance": "Target for data vendors",
    "signal_category": "technology",
    "regions_mentioned": [
      "U.S."
    ],
    "vendors_mentioned": [
      "U.S. Food and Drug Administration (FDA)"
    ],
    "technologies_mentioned": [
      "CAR-T"
    ]
  }
}

Long text fields are shortened on this page.

Looking up one signal by its id is free. Enrich costs 2 credits per signal returned; a call with no results is free.